Secondary Liver Cancer Survival Rate by Age: What to Know

Survival after secondary liver cancer, where cancer from another organ has spread to the liver, generally declines with advancing age, but the relationship between age and outcomes is far less straightforward than a simple downward curve suggests. Large population-level data show that older patients have shorter median survival on average, yet carefully selected older adults who receive aggressive treatment can achieve outcomes close to their younger counterparts. The gap between these two realities comes down to fitness, the origin of the primary tumor, the timing of metastases, and whether a patient actually receives treatment at all.

What the Population-Level Numbers Show

Using broad cancer registry data, researchers have consistently found that advancing age is an independent predictor of worse outcomes in secondary liver cancer. A large analysis of the U.S. SEER database confirmed that older age, along with factors like male sex, Black race, and certain aggressive primary tumor types, was independently linked to poorer prognosis for patients with liver metastases.¹ A separate pan-cancer population study echoed this pattern, finding both higher incidence of liver metastases and worse prognosis in older adults compared with younger patients.²

For the most commonly studied scenario, colorectal cancer that spreads to the liver, a population-based study published in JAMA Oncology provides concrete numbers. Five-year overall survival was roughly 49% for patients younger than 65, dropped to about 44% for those aged 65 to 74, and fell further to around 28% for patients 75 and older.³ Those numbers encompass all patients in the registry, including many who never received curative-intent treatment. That distinction matters enormously, because treatment selection is one of the biggest reasons the age gap looks so wide in population data.

Why Younger Patients Are Not Always Better Off Biologically

An interesting wrinkle in the data is that younger patients tend to develop liver metastases at higher rates in the first place. A 2025 study in JAMA Network Open found that the cumulative incidence of colorectal liver metastases was highest in patients younger than 50, reaching about 27% at five-year follow-up, and was also elevated in men.⁴ This may seem counterintuitive if you expect older age to be the biggest risk factor. The explanation appears to lie in tumor biology: younger patients can harbor more aggressive primary tumors with a higher propensity to metastasize early. In colorectal cancer, younger-onset disease has been linked to more advanced stages at diagnosis and potentially different molecular profiles. So while older patients have worse survival on average once metastases appear, younger patients should not assume their age alone is protective.

Surgical Resection and the Age Debate

Liver surgery to remove metastases remains the treatment most likely to offer long-term survival or even cure in secondary liver cancer, particularly from colorectal primaries. The central question for older adults is whether age itself makes surgery too risky, or whether it is the conditions that accumulate with age that create the danger.

The evidence points firmly toward the latter. A study examining colorectal liver metastasis resection across three age groups found that five-year overall survival was about 29% for patients 75 and older, about 33% for patients 65 to 74, and roughly 44% for younger patients. Post-operative complications were slightly more common in the oldest group but not statistically different, and disease-free survival after surgery was similar across all age brackets.⁵ In other words, when older patients make it through surgery, the cancer behaves similarly regardless of age. The gap in overall survival likely reflects competing causes of death in older people rather than the cancer itself being harder to control.

Even more striking, a study from a high-volume surgical center found virtually identical five-year survival after liver resection in patients over 75 compared with those under 75: about 58% versus 56%, with no statistically significant difference. Complication rates and hospital stays were comparable.⁶ The discrepancy between this result and the previous one likely reflects patient selection. In specialized centers that carefully screen older patients for fitness before offering surgery, the age penalty can nearly vanish. In broader population data that include older patients who were either too frail for surgery or never offered it, the gap widens considerably.

A nationwide population-based study confirmed this dynamic on a larger scale: in multivariable analysis, patients aged 70 to 80 had a modestly higher hazard of death (about 20% higher) and patients over 80 had about a 50% increase, even after accounting for other risk factors. But the same analysis showed that comorbidity burden, tumor number, tumor size, synchronous disease, and major surgical complications were all independent risk factors too.⁷ Age adds risk, but it is one factor among many rather than a reason to rule out surgery automatically.

Non-Surgical Treatments Show Less Age Penalty

Not every patient is a candidate for liver resection. Thermal ablation, which uses heat to destroy small tumors through a needle inserted into the liver, has become a standard alternative. A 10-year registry from Amsterdam tracking patients who received thermal ablation for colorectal liver metastases reported a median overall survival of about 54 months after the first procedure, with five-year survival around 46% and 10-year survival near 27%.⁸ While this registry did not break down results by age group, ablation’s minimally invasive nature makes it particularly relevant for older patients who cannot tolerate major surgery. Recovery is faster and complication rates are lower, which widens the pool of older adults who can receive treatment.

Radioembolization, a procedure that delivers targeted radiation through the liver’s blood supply, also appears to erase much of the age gap. A study comparing outcomes in elderly and non-elderly patients receiving yttrium-90 radioembolization found that median survival was similar between the two groups for colorectal liver metastases (roughly 377 days versus 365 days) and showed no meaningful difference for other tumor types either.⁹ These numbers represent median survival in patients with more advanced disease who were not surgical candidates, so they are lower than the surgical figures above, but the key takeaway is the absence of an age penalty when the same treatment is delivered.

When Liver Metastases Appear Relative to the Primary Tumor

The timing of liver metastases, whether they are found at the same time as the original cancer (synchronous) or develop later (metachronous), influences survival independently of age. A large JAMA Network Open study showed that synchronous liver metastases from colorectal cancer carried worse outcomes than metachronous ones, and that being 75 or older at diagnosis further reduced survival in both groups.¹⁰ Among patients under 75 with metachronous disease, roughly 18% were alive at five years. For synchronous disease in the same age group, that dropped to about 9%.

A study examining patients who underwent liver resection for these two categories confirmed the pattern: synchronous metastases carried about twice the hazard of death compared to metachronous ones, and increasing age independently raised the risk as well.¹¹ For older patients, this means the combination of synchronous presentation and advanced age creates a particularly challenging scenario. On the other hand, an older patient whose liver metastases develop a year or more after successful treatment of the primary tumor is in a meaningfully different situation from someone diagnosed with both at once.

What Matters Beyond the Number of Metastases

Tumor burden within and beyond the liver plays a major role in outcomes for every age group, but certain features are especially predictive in older adults being evaluated for surgery. A study focused on first and repeat liver resections in elderly patients identified three independent risk factors for recurrence and poor disease-free survival: extrahepatic disease (cancer that has also spread to sites outside the liver), three or more liver metastases, and very high levels of the blood marker CEA (above 200 ng/mL).¹² The nationwide population study noted earlier confirmed that having more than three liver metastases, tumors larger than 4 centimeters, and extrahepatic disease all independently worsened survival regardless of age.⁷

The practical implication is that an otherwise healthy 78-year-old with a single small liver metastasis from a colon cancer treated two years earlier is in a fundamentally different position from a 78-year-old with five liver lesions, lung nodules, and cancer spreading at the same time as the original tumor. Age is only one variable in a much longer equation, and the other variables can easily override it.

Frailty and Muscle Mass vs. Calendar Age

One of the most consistent themes in the recent literature is that biological fitness predicts outcomes better than the number on a birth certificate. Frailty, a clinical syndrome of reduced physiological reserve, has a dramatic impact. A study of older adults with liver tumors found that being classified as frail, compared with being robust, was associated with roughly 2.6 times the risk of death after adjusting for age, disease stage, and other factors.¹³ That study focused on primary liver cancer rather than liver metastases, but the principle applies broadly: two patients of the same age can have wildly different trajectories depending on their overall physical reserve.

Sarcopenia, the loss of skeletal muscle mass and quality that accelerates with aging, has emerged as a powerful predictor in secondary liver cancer specifically. A meta-analysis of patients who received local therapy for colorectal liver metastases found that low muscle mass raised the hazard of death by about 35%, and low muscle density (indicating fat infiltration of remaining muscle) nearly doubled it.¹⁴ A prospective study confirmed that preoperative sarcopenia predicted worse overall survival for up to four years after liver resection for colorectal metastases.¹⁵

Even in patients whose tumors cannot be surgically removed, sarcopenia matters. A study of patients with unresectable colorectal liver metastases treated with chemoembolization found that the group without sarcopenia had a median overall survival of nearly 15 months compared with about 10 months for those with sarcopenia.¹⁶ The difference held up even after controlling for other known risk factors.

What makes sarcopenia particularly relevant to older adults is that it overlaps heavily with aging but is not the same thing. A 70-year-old who has maintained muscle mass through activity and nutrition can be measurably stronger and have a better prognosis than a sedentary 60-year-old who has lost significant muscle. CT scans done as part of routine cancer staging can be used to measure muscle mass, giving clinicians an objective tool beyond just asking a patient how they feel.

Are Older Patients Being Undertreated?

A persistent concern in oncology is that older patients are systematically undertreated, and the data suggest this worry is warranted. Older adults are underrepresented in the clinical trials that generate the evidence doctors rely on. In major phase III trials of immunotherapy for liver cancer, patients over 65 made up roughly half of trial participants despite representing a much larger share (over 70%) of the real-world patient population.¹⁷ When older patients are absent from trials, doctors have less confidence applying the results to them, which can create a self-reinforcing cycle of under-treatment.

A systematic review examining the impact of age on clinical outcomes in liver cancer found that differences in who received curative treatment were driven by factors like liver function, performance status, and the burden of other medical conditions, rather than age itself.¹⁸ That is a reasonable basis for treatment decisions in individual cases, but population-level patterns suggest age alone is still influencing who gets offered curative options. When the surgical data consistently show that well-selected older patients do nearly as well as younger ones, and population-level data show a large survival gap, the likeliest explanation is that many fit older adults are never given the chance.

If you are an older adult facing a diagnosis of secondary liver cancer, or caring for someone who is, the relevant question is not “what is the survival rate for my age group” but rather “am I fit enough to benefit from the treatments that improve survival.” Asking about a geriatric assessment, where clinicians formally evaluate functional status, cognitive health, nutrition, and comorbidities, can help ensure that calendar age alone is not the reason a treatment option is taken off the table.

Where the Primary Cancer Started

Age is far from the only demographic factor in liver metastasis prognosis, and the type of primary cancer that spread to the liver may ultimately matter more. The SEER database analysis found that patients whose primary cancer originated in the pancreas, lung, or stomach had particularly poor outcomes compared with other primary sites.¹ Colorectal liver metastases generally have the most favorable prognosis among common cancers that spread to the liver, which is why most of the surgical and ablation survival data focuses on that population. Neuroendocrine tumors that metastasize to the liver also tend to have a more indolent course, while metastases from melanoma, sarcoma, or upper gastrointestinal cancers carry shorter expected survival at any age.

For older adults, this means that a conversation about prognosis needs to start with the biology of the primary tumor. A 75-year-old with two liver metastases from a well-differentiated colon cancer is in a fundamentally different category from a 55-year-old with liver metastases from pancreatic cancer, even though the younger patient has a numerical age advantage. The five-year survival figures discussed earlier, ranging from roughly 28% to 58% depending on age and treatment center, apply specifically to colorectal liver metastases. For liver metastases from pancreatic or gastric primary tumors, five-year survival is measured in single digits for all age groups, making the age variable far less consequential relative to tumor type.